Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
The Global Biosimilar Monoclonal Antibodies (mAbs) Market will grow by USD 8.65 bn during 2020-2024
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
08:48pm, Monday, 03'rd Aug 2020
REDWOOD CITY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors e
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Earnings Preview: Coherus BioSciences (CHRS) Q2 Earnings Expected to Decline
04:33pm, Thursday, 30'th Jul 2020
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Value Stocks In The Healthcare Sector
12:00am, Monday, 27'th Jul 2020
What are Value Stocks?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E...
Healthcare Dashboard For July
12:35pm, Tuesday, 21'st Jul 2020
A dashboard with metrics of value, quality and momentum by industries. Value and quality scores relative to historical averages.
Bank of America Begins Coverage on Coherus Biosciences (NASDAQ:CHRS)
05:48am, Sunday, 19'th Jul 2020
Bank of America began coverage on shares of Coherus Biosciences (NASDAQ:CHRS) in a research note issued to investors on Thursday morning, Benzinga reports. The firm issued a neutral rating and a $20.0
BofA Securities Begins Coverage on Coherus Biosciences (NASDAQ:CHRS)
05:48am, Sunday, 19'th Jul 2020
BofA Securities assumed coverage on shares of Coherus Biosciences (NASDAQ:CHRS) in a report issued on Thursday morning, Briefing.com Automated Import reports. The brokerage issued a neutral rating and
Coherus BioSciences Announces New Employment Inducement Grants
01:30pm, Friday, 17'th Jul 2020
REDWOOD CITY, Calif., July 17, 2020 -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 16, 2020, the compensation.
Coherus BioSciences to Report Second Quarter Financial Results on August 6th
01:30pm, Thursday, 16'th Jul 2020
REDWOOD CITY, Calif., July 16, 2020 -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released.
Coherus Biosciences (NASDAQ:CHRS) Rating Lowered to Strong Sell at BidaskClub
05:14am, Thursday, 16'th Jul 2020
Coherus Biosciences (NASDAQ:CHRS) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Thursday, BidAskClub reports. Several ot
Zacks: Brokerages Expect Coherus Biosciences Inc (NASDAQ:CHRS) Will Post Quarterly Sales of $100.33 Million
01:58am, Wednesday, 15'th Jul 2020
Analysts expect Coherus Biosciences Inc (NASDAQ:CHRS) to announce sales of $100.33 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Cohe
Here's Why Coherus BioSciences (NASDAQ:CHRS) Can Manage Its Debt Responsibly
07:49pm, Tuesday, 14'th Jul 2020
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
DNB Asset Management AS Invests $318,000 in Coherus Biosciences Inc (NASDAQ:CHRS)
05:38am, Tuesday, 14'th Jul 2020
DNB Asset Management AS bought a new position in Coherus Biosciences Inc (NASDAQ:CHRS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange
